Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody
Author Information
Author(s): Adekar Sharad P., Takahashi Tsuyoshi, Jones R. Mark, Al-Saleem Fetweh H., Ancharski Denise M., Root Michael J., Kapadnis B. P., Simpson Lance L., Dessain Scott K.
Primary Institution: Lankenau Institute for Medical Research
Hypothesis
Can a human monoclonal antibody specific for the catalytic light chain of botulinum neurotoxin effectively neutralize its effects in vivo and in vitro?
Conclusion
The 4LCA antibody can potently inhibit botulinum neurotoxin A in vivo and in vitro, suggesting its potential as a therapeutic component for botulinum exposure.
Supporting Evidence
- The 4LCA antibody showed complete protection in mice against high doses of botulinum toxin.
- In cell culture, the 4LCA antibody inhibited 92% of the cleavage of SNAP-25 by botulinum neurotoxin.
- The antibody was able to directly inhibit the catalytic activity of the botulinum neurotoxin in vitro.
Takeaway
Scientists created a special antibody that can stop a dangerous toxin from making people sick, and it works really well in tests.
Methodology
The study involved cloning a human antibody specific for the light chain of botulinum neurotoxin and testing its neutralization ability in mouse models and cell cultures.
Limitations
The study's findings may not fully translate to human applications without further testing.
Participant Demographics
The antibody was derived from a volunteer who had received a botulinum toxoid vaccine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website